VivoSeq
Oncology

Peritoneal Mesothelioma

6

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Peritoneal Mesothelioma is an early-stage landscape with 6 programs across 6 companies. The most active players are Merck & Co., Teva, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1Arcus Biosciences logo

Arcus Biosciences

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

5 of 7 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody229%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT04847063·60 enrolled
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Active, not recruiting·HHospices Civils de Lyon·Phase 2·NCT06790706·27 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)